KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Payables (2017 - 2025)

Bionano Genomics' Payables history spans 7 years, with the latest figure at $15.8 million for Q3 2025.

  • For Q3 2025, Payables fell 33.14% year-over-year to $15.8 million; the TTM value through Sep 2025 reached $15.8 million, down 33.14%, while the annual FY2024 figure was $27.3 million, 65.92% down from the prior year.
  • Payables for Q3 2025 was $15.8 million at Bionano Genomics, down from $18.0 million in the prior quarter.
  • Across five years, Payables topped out at $80.2 million in Q4 2023 and bottomed at $2.2 million in Q1 2021.
  • The 5-year median for Payables is $15.4 million (2023), against an average of $18.7 million.
  • The largest annual shift saw Payables surged 539.76% in 2023 before it crashed 65.92% in 2024.
  • A 5-year view of Payables shows it stood at $10.8 million in 2021, then rose by 16.39% to $12.5 million in 2022, then soared by 539.76% to $80.2 million in 2023, then plummeted by 65.92% to $27.3 million in 2024, then plummeted by 42.12% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Payables are $15.8 million (Q3 2025), $18.0 million (Q2 2025), and $19.6 million (Q1 2025).